Daniel S. Clevenger

Partner - Boston

Bio photo for Daniel Clevenger
Download Media Photo

Contact Information

617.832.1283

617.832.7000

dclevenger@foleyhoag.com Download vCard

Dan Clevenger is a partner in the firm’s Business Department. Dan helps technology, energy and cleantech and life sciences companies at all stages of growth, as well as their boards, as they navigate the legal, regulatory, governance and business hurdles companies face in the current market.

Over his 20+ year career, Dan has partnered with high-growth companies on a wide range of strategic transactions and matters, including public offerings of debt and equity securities, venture capital investments, and mergers and acquisitions. Dan has a particular interest in the energy and cleantech sector. Dan frequently works with solar project developers on the sale of operating and development portfolios. 

In addition to his transactional work, Dan also has extensive experience advising public companies on compliance with United States federal securities laws, including public reporting, proxy solicitations and shareholder communications. Dan also advises private and public companies on governance related matters, including board composition and other good governance practices, drafting compliance policies and committee charters, and ESG-related reporting and SEC filings and other disclosures. 

More »

Education:

  • College of William and Mary, J.D., 1999
  • Virginia Tech, B.S. in Biochemistry, 1996

Representative Experience

  • MDxHealth SA (Nasdaq/Euronext: MDXH), a foreign private issuer, in its acquisition of the OncoType DX Genomic Prostate Score business from Exact Sciences Corporation (Nasdaq: EXAS) for cash and equity consideration of up to $100 million, including a multi-year earn-out arrangement. 
  • Represented Novellus Therapeutics, a developer of novel medicines intended for the treatment of pediatric disease, in its sale to Brooklyn ImmunoTherapeutics (NYSE: BTX) for $125 million 
  • Represented computer-aided engineering company Exa Corporation (Nasdaq :EXA) in its $400M sale to French software company Dassault. 
  • Represented Living Proof, Inc. in its acquisition by Unilever.
  • Represented Applied Genetic Technologies Corporation, a Florida-based biotechnology company, in its initial public offering and subsequent follow-on offering.
  • Represented Hittite Corporation in its sale to Analog Devices, Inc.
  • Represented lead investor in $75 million Series B financing of a pharmaceuticals company.
  • Represented a healthcare information management company and its equity holders in $68.5 million sale to a strategic buyer.
  • Represented Exa Corporation, a Massachusetts-based provider of software simulation tools, in its initial public offering.
  • Represented Art Technology Group, a provider of e-commerce software, in its $1.0 billion sale to Oracle Corporation.
  • Represented lead investor in $55 million investment in development stage biopharmaceutical company.
  • Represented Alere Inc., NYSE-listed medical device manufacturer, in private and public offerings of debt securities with an aggregate principal amount of $1.05 billion.
Add to Bio Folder

Download Bio

Bar Admissions

  • Massachusetts
  • Virginia